Overview
Sirtex develops liver-directed cancer therapy using SIR-Spheres Y-90 resin microspheres to treat inoperable liver tumors through selective internal radiation therapy (SIRT). The tiny beads are delivered via a catheter into the liver arteries feeding the tumor, where they lodge in small vessels and emit radiation locally to kill cancer cells while minimizing damage to healthy tissue. Its focus on a catheter-based, liver-specific approach with an established regulatory path distinguishes it from external-beam radiation or systemic chemotherapy. The goal is to provide effective, targeted radiation therapy for liver cancer and expand global access to SIRT.
Work here?Claim your company
Simplify's take
What believers are saying
- FDA HCC approval in July 2025 unlocks a large, previously inaccessible liver cancer market.
- Expanded European labeling in September 2025 increases addressable patients and physician adoption opportunities.
- LAVA commercialization and Magle collaboration diversify revenue beyond microspheres, reducing single-product concentration.
What critics are saying
- Sirtex still depends heavily on SIR-Spheres; any HCC launch miss hits 2026 growth immediately.
- Mimic competitors like Boston Scientific and Terumo can commoditize embolization workflows by 2027.
- A safety or reimbursement setback in U.S. HCC adoption could crush the private valuation quickly.
What makes Sirtex unique
- SIR-Spheres won FDA HCC approval on July 7, 2025, unique in U.S. radioembolization.
- DOORwaY90 hit 100% local tumor control on April 13, 2026, strengthening clinical differentiation.
- Expanded CE Mark on September 8, 2025 broadens SIR-Spheres across primary and secondary liver cancers.
Help us improve and share your feedback! Did you find this helpful?